anti-EGFR antibody-drug conjugate CPO301

{
  "id": "MLC-T-ONC-010587",
  "term": "anti-EGFR antibody-drug conjugate CPO301",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) consisting of a monoclonal antibody directed against the epidermal growth factor receptor (EGFR; HER1; ErbB1) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-EGFR ADC CPO301, the monoclonal antibody moiety binds to EGFR on tumor cell surfaces. Upon binding and internalization, the cytotoxic agent is released and kills the EGFR-expressing cancer cells, through an as of yet unknown mechanism of action. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.",
  "synonyms": [
    "anti-EGFR ADC CPO301",
    "anti-EGFR antibody-drug conjugate SYS6010"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-egfr-antibody-drug-conjugate-cpo301/"
}